On March 21, 2024, the House Energy and Commerce Health Subcommittee held a hearing on Food and Drug Administration (FDA) regulation of laboratory developed tests (LDTs) and the impact of FDA’s proposed rule on patient access.
On March 21, 2024, the House Energy and Commerce Health Subcommittee held a hearing on Food and Drug Administration (FDA) regulation of laboratory developed tests (LDTs) and the impact of FDA’s proposed rule on patient access.